Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

Recent studies have indicated that afatinib is beneficial for patients with non‐small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, while the effectiveness of afatinib rechallenge has not been fully defined. Here, we report a long‐term survival case o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Masuda, Tomomi, Sunaga, Noriaki, Kasahara, Norimitsu, Takehara, Kazutaka, Yatomi, Masakiyo, Hara, Kenichiro, Koga, Yasuhiko, Maeno, Toshitaka, Hisada, Takeshi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2020
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7396375/
https://ncbi.nlm.nih.gov/pubmed/32529804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13532
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados